HC Wainwright & Co. Maintains Buy on WAVE Life Sciences, Lowers Price Target to $18

Benzinga Newsdesk www.benzinga.com Neutral 55.6%

Neg 0% Neu 55.6% Pos 0%

HC Wainwright & Co. analyst Andrew S. Fein maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and lowers the price target from $30 to $18.